{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T06:56:35Z","timestamp":1782543395261,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.vph.2019.106566","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T11:30:19Z","timestamp":1560511819000},"page":"106566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort"],"prefix":"10.1016","volume":"120","author":[{"given":"Alexander","family":"Dressel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Fath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. John","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja B.","family":"Grammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"M\u00e4rz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.vph.2019.106566_bb0005","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2019.106566_bb0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.vph.2019.106566_bb0015","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","article-title":"Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.vph.2019.106566_bb0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.vph.2019.106566_bb0025","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.001800","article-title":"Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis","volume":"1","author":"Jones","year":"2012","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.vph.2019.106566_bb0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2017.11.020","article-title":"Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany","volume":"268","author":"M\u00e4rz","year":"2018","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.vph.2019.106566_bb0035","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"issue":"23","key":"10.1016\/j.vph.2019.106566_bb0040","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9965","key":"10.1016\/j.vph.2019.106566_bb0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vph.2019.106566_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am. Heart J."},{"issue":"19","key":"10.1016\/j.vph.2019.106566_bb0055","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur. Heart J."},{"issue":"22","key":"10.1016\/j.vph.2019.106566_bb0060","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.vph.2019.106566_bb0065","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.vph.2019.106566_bb0070","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.vph.2019.106566_bb0075","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.vph.2019.106566_bb0080","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA"},{"issue":"1 Suppl 1","key":"10.1016\/j.vph.2019.106566_bb0085","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1517\/14622416.2.1.S1","article-title":"Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease","volume":"2","author":"Winkelmann","year":"2001","journal-title":"Pharmacogenomics"},{"issue":"8","key":"10.1016\/j.vph.2019.106566_bb0090","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.vph.2019.106566_bb0095","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/STROKEAHA.110.592642","article-title":"Stroke incidence and survival in Ludwigshafen am Rhein, Germany: the Ludwigshafen Stroke Study (LuSSt)","volume":"41","author":"Palm","year":"2010","journal-title":"Stroke"},{"issue":"14","key":"10.1016\/j.vph.2019.106566_bb0100","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.113.004042","article-title":"Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study","volume":"129","author":"Moran","year":"2014","journal-title":"Circulation"},{"issue":"9859","key":"10.1016\/j.vph.2019.106566_bb0105","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vph.2019.106566_bb0110","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/europace\/eur116","article-title":"The costs of atrial fibrillation in patients with cardiovascular comorbidities--a longitudinal analysis of German health insurance data","volume":"13","author":"Reinhold","year":"2011","journal-title":"Europace"},{"issue":"5","key":"10.1016\/j.vph.2019.106566_bb0115","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1161\/01.STR.0000217450.21310.90","article-title":"Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project","volume":"37","author":"Kolominsky-Rabas","year":"2006","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.vph.2019.106566_bb0120","first-page":"202","article-title":"NHG-Standpunt Diagnostiek en behandeling van familiaire hypercholesterolemie","volume":"49","author":"Walma","year":"2006","journal-title":"Huisarts Wet"},{"issue":"10059","key":"10.1016\/j.vph.2019.106566_bb0125","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vph.2019.106566_bb0130","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","article-title":"Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease","volume":"2","author":"Fonarow","year":"2017","journal-title":"JAMA Cardiol."},{"issue":"19","key":"10.1016\/j.vph.2019.106566_bb0135","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.vph.2019.106566_bb0140","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/clc.22924","article-title":"PCSK9 inhibitor valuation: a science-based review of the two recent models","volume":"41","author":"Baum","year":"2018","journal-title":"Clin. Cardiol."},{"issue":"6","key":"10.1016\/j.vph.2019.106566_bb0145","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/clc.22535","article-title":"Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States","volume":"39","author":"Gandra","year":"2016","journal-title":"Clin. Cardiol."},{"issue":"6","key":"10.1016\/j.vph.2019.106566_bb0150","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/13696998.2017.1284078","article-title":"Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context","volume":"20","author":"Toth","year":"2017","journal-title":"J. Med. Econ."},{"issue":"5","key":"10.1016\/j.vph.2019.106566_bb0155","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/PL00001961","article-title":"Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial","volume":"25","author":"Szucs","year":"2000","journal-title":"Herz"},{"key":"10.1016\/j.vph.2019.106566_bb0160","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"issue":"5\u20136","key":"10.1016\/j.vph.2019.106566_bb0165","first-page":"650","article-title":"Prevalence of myocardial infarction and coronary heart disease in adults aged 40\u201379 years in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)","volume":"56","author":"Gosswald","year":"2013","journal-title":"Bundesgesundheitsbl. Gesundheitsforsch. Gesundheitsschutz"},{"key":"10.1016\/j.vph.2019.106566_bb0170","series-title":"Gesundheit in Deutschland - Gesundheitsberichterstattug des Bundes gemeinsam getragen von RKI und Destatis, Berlin","author":"Robert Koch-Institut","year":"2015"},{"issue":"S1","key":"10.1016\/j.vph.2019.106566_bb0175","article-title":"Atherothrombotic risk stratification and magnitude of benefit of evolocumab in FOURIER","volume":"126","author":"Bohula","year":"2017","journal-title":"AHA Scientific Sessions"},{"issue":"14","key":"10.1016\/j.vph.2019.106566_bb0180","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/eurheartj\/ehx549","article-title":"2017 update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia","volume":"39","author":"Landmesser","year":"2018","journal-title":"Eur. Heart J."},{"issue":"27","key":"10.1016\/j.vph.2019.106566_bb0185","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/eurheartj\/ehx710","article-title":"\u2018Highest risk-highest benefit\u2019 strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies","volume":"39","author":"Annemans","year":"2018","journal-title":"Eur. Heart J."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189118304336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189118304336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T07:44:51Z","timestamp":1567410291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189118304336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":37,"alternative-id":["S1537189118304336"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2019.106566","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2019.106566","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106566"}}